Search results for "Metabolic disease"

showing 10 items of 778 documents

Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype

2017

BACKGROUND: Dyslipidemia is common in women with polycystic ovary syndrome (PCOS) but its prevalence in different PCOS phenotypes is still largely unknown. METHODS: We measured plasma lipids and lipoproteins in 35 anovulatory PCOS (age: 25 ± 6 years, BMI: 28 ± 6 kg/m2), 15 ovulatory PCOS (age: 30 ± 6 years, BMI: 25 ± 3 kg/m2) and 27 healthy women (controls) age- and BMI-matched with ovulatory PCOS. PCOS was diagnosed by the presence of clinical or biologic hyperandrogenism associated with chronic anovulation and/or polycystic ovaries at ultrasound. In women with normal menses chronic anovulation was indicated by low serum progesterone levels (<9.54 nmol/l) during midluteal phase (days 21…

AdultOvulationmedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseases10265 Clinic for Endocrinology and Diabetology610 Medicine & healthBiologyAnovulationchemistry.chemical_compoundInsulin resistancepolycystic ovary syndrome lipids lipoproteins cardiovascular riskRisk FactorsInternal medicinemedicineHumansTriglyceridesTestosteroneDyslipidemiasTriglycerideRehabilitationHyperandrogenismObstetrics and Gynecologynutritional and metabolic diseases2729 Obstetrics and GynecologyCholesterol LDL2743 Reproductive MedicineAtherosclerosismedicine.diseasePolycystic ovarySettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsCholesterolEndocrinologyReproductive Medicinechemistry10036 Medical ClinicFemalelipids (amino acids peptides and proteins)DyslipidemiaPolycystic Ovary SyndromeLipoprotein
researchProduct

Socio-economic factors and prevalence of underweight and overweight among female students in Poland.

2005

The aim of the work was to assess the prevalence of underweight among young women and to analyse factors contributing to this phenomenon. The study group consisted of 718 female students aged 18-24 years. Underweight, overweight and obesity was classified according to BMI and WHO criteria. To assess the socio-economic status (SES), place of residence before entering the university and education of parents were used. Variables characterising lifestyle such as sports activity, cigarette smoking and alcohol drinking were also taken into account. In the studied group, the prevalence of underweight was much higher than the prevalence of overweight and obesity (15.3% and 3.5%, respectively). Low …

AdultPediatricsmedicine.medical_specialtyAdolescentSelf-conceptOverweightBody Mass IndexThinnessmedicinePrevalenceHumansObesityStudentsFemale studentsLife Stylebusiness.industrynutritional and metabolic diseasesOverweightmedicine.diseaseObesitySelf ConceptSocioeconomic FactorsAnthropologyEducational StatusWho criteriaResidenceFemalePolandUnderweightmedicine.symptombusinessBody mass indexDemographyHomo : internationale Zeitschrift fur die vergleichende Forschung am Menschen
researchProduct

Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome.

2013

Background Obesity is known to underlie, at least partially, dyslipidemia in polycystic ovary syndrome (PCOS), but it is unclear whether PCOS status per se increases the risk of alterations of lipoprotein subfractions, which differ in size and atherogenic potential. Our objective was to evaluate whether PCOS influences lipoprotein profile and LDL and HDL subfractions and to study the impact of obesity on these parameters. Materials and methods This was a case–control study conducted in an academic medical centre. The study population consisted of 54 women of fertile age with PCOS and 60 controls adjusted for age and BMI. Biochemical lipid profile and LDL and HDL lipoprotein subfractions (me…

AdultVery low-density lipoproteinmedicine.medical_specialtyendocrine system diseasesClinical BiochemistryBiochemistryBody Mass Indexchemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumansObesityDyslipidemiasmedicine.diagnostic_testCholesterolbusiness.industryCholesterol HDLCase-control studynutritional and metabolic diseasesCholesterol LDLGeneral MedicineAtherosclerosismedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsEndocrinologychemistryCase-Control StudiesFemalelipids (amino acids peptides and proteins)Lipid profilebusinessBody mass indexDyslipidemiaPolycystic Ovary SyndromeLipoprotein
researchProduct

Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression.

2009

Hurler-Scheie syndrome is caused by alpha-l-iduronidase deficiency. Enzyme replacement therapy (ERT) can improve physical capacity and reduces organomegaly. However, the effect on bradytrophic connective tissue is limited. As intravenously administered enzyme cannot cross the blood-brain barrier, the therapy of choice for the more severe Hurler syndrome is haematopoietic stem cell transplantation (HCT). In the more attenuated Scheie syndrome, neurological impairment is less severe; therefore, ERT may be appropriate to treat these patients. Information on long-term outcome in Scheie patients undergoing ERT is scarce. We report a 38-year-old female Scheie patient who has been on ERT for 8 yea…

Adultcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyMucopolysaccharidosis IMyelopathyIduronidaseSpinal cord compressionMucopolysaccharidosis IGeneticsmedicineHumansEnzyme Replacement TherapyHurler syndromeGenetics (clinical)business.industryHematopoietic Stem Cell Transplantationnutritional and metabolic diseasesBrainEnzyme replacement therapymedicine.diseaseSpinal cordSurgeryTransplantationmedicine.anatomical_structureCervical VertebraeDisease ProgressionFemaleScheie syndromebusinessSpinal Cord CompressionJournal of inherited metabolic disease
researchProduct

Identifying women with gestational diabetes based on maternal characteristics: an analysis of four Norwegian prospective studies

2021

Abstract Background There is still no worldwide agreement on the best diagnostic thresholds to define gestational diabetes (GDM) or the optimal approach for identifying women with GDM. Should all pregnant women perform an oral glucose tolerance test (OGTT) or can easily available maternal characteristics, such as age, BMI and ethnicity, indicate which women to test? The aim of this study was to assess the prevalence of GDM by three diagnostic criteria and the predictive accuracy of commonly used risk factors. Methods We merged data from four Norwegian cohorts (2002–2013), encompassing 2981 women with complete results from a universally offered OGTT. Prevalences were estimated based on the f…

Adultmedicine.medical_specialtyDiagnostic criteriaendocrine system diseasesReproductive medicine:Medisinske Fag: 700::Klinisk medisinske fag: 750::Gynekologi og obstetrikk: 756 [VDP]NorwegianWorld Health OrganizationLogistic regressionGestational diabetes mellitusBody Mass IndexPredictive Value of TestsRisk FactorsPregnancyEthnicityPrevalencemedicineScreening methodHumansProspective StudiesProspective cohort studyPregnancyDiagnostic Tests RoutineNorwayObstetricsbusiness.industryResearchAge FactorsObstetrics and Gynecologynutritional and metabolic diseasesGynecology and obstetricsGlucose Tolerance Testmedicine.diseasePre pregnancy BMIlanguage.human_languagePeer reviewGestational diabetesDiabetes GestationalVDP::Medisinske Fag: 700::Helsefag: 800ScreeningRG1-991languageFemalebusiness
researchProduct

Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.

2006

Abstract Context: An altered lipid profile is common in polycystic ovary syndrome (PCOS) and is usually characterized by increased triglycerides and low high-density lipoprotein (HDL)-cholesterol levels. In the general population, these alterations are often associated with the increase of small low-density lipoproteins (LDLs) in the so-called “atherogenic lipoprotein phenotype” (ALP) that determines a further increase of cardiovascular risk. In this study, we evaluated the presence of ALP in the plasma of women with PCOS. Setting: Measurements and analysis of LDL size were performed at the Clinic of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital, Zurich. PCOS patients…

Adultmedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryPopulationClinical nutritionBiologyBiochemistryAnovulationEndocrinologyDiabetes mellitusInternal medicinemedicineHumansInsulinParticle SizeeducationTriglyceridesAtherogenic lipoprotein low-density lipoproteins polycystic ovary syndromeeducation.field_of_studymedicine.diagnostic_testBiochemistry (medical)HyperandrogenismCholesterol HDLnutritional and metabolic diseasesmedicine.diseasePolycystic ovaryLipoproteins LDLEndocrinologyPhenotypelipids (amino acids peptides and proteins)FemaleLipid profileLipoproteinPolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

2020

Abstract Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and immunosuppression for a minimum of 30 days after stopping daily PEX. We performed a retrospective, observational analysis on the use of caplacizumab in 60 patients from 29 medical centers in Germany during acute disease management. Caplacizumab led to a rapid normalization of the platelet count (median, 3 days; mean 3.78 days). One patient died after late treatment initiation due to aTTP-associated complications. In 2 patients with…

Adultmedicine.medical_specialtyExacerbationmedicine.medical_treatmentThrombotic thrombocytopenic purpuraMedizin030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicineHumansRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpuraPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain Antibodiesmedicine.diseasePurpuraDisease PresentationCardiovascular and Metabolic Diseases030220 oncology & carcinogenesisCaplacizumabmedicine.symptombusiness
researchProduct

Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.

2013

Abstract Objective To determine the spectrum of gene mutations and the genotype–phenotype correlations in patients with Autosomal Dominant Hypercholesterolemia (ADH) identified in Italy. Methods The resequencing of LDLR , PCSK9 genes and a selected region of APOB gene were conducted in 1018 index subjects clinically heterozygous ADH and in 52 patients clinically homozygous ADH. The analysis was also extended to 1008 family members of mutation positive subjects. Results Mutations were detected in 832 individuals: 97.4% with LDLR mutations, 2.2% with APOB mutations and 0.36% with PCSK9 mutations. Among the patients with homozygous ADH, 51 were carriers of LDLR mutations and one was an LDLR / …

Adultmedicine.medical_specialtyHeterozygoteSettore MED/09 - Medicina InternaApolipoprotein BCoronary DiseaseBiologyGene mutationmedicine.disease_causeHyperlipoproteinemia Type IITendonschemistry.chemical_compoundReference ValuesInternal medicinemedicineXanthomatosisHumansGeneAllelesGenetic Association StudiesAgedGeneticsMutationCholesterolPCSK9Cholesterol HDLSerine EndopeptidasesSmokingAlcohol Dehydrogenasenutritional and metabolic diseasesCholesterol LDLMiddle AgedEndocrinologyPhenotypechemistryItalyLDL receptorMutationbiology.proteinAutosomal dominanthypercholesterolemia LDL receptor Apolipoprotein B PCSK9 Mutationslipids (amino acids peptides and proteins)Allelic heterogeneityFemaleProprotein ConvertasesProprotein Convertase 9Cardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

Maternal-fetal Complications in Pregnancy: A Retrospective Comparison Between Type 1 and Type 2 Diabetes Mellitus

2021

Abstract Background The aim of the study was a retrospective comparison of the differences in maternal-foetal outcomes between women with type 1 and type 2 diabetes mellitus (T1DM and T2DM). Methods A cohort of 135 patients with pregestational diabetes, 73 with T1DM (mean age 29 ± 5 years) and 62 with T2DM (mean age 33 ± 6 years), in intensive insulin treatment throughout pregnancy were evaluated. Clinical and metabolic parameters and the prevalence of maternal and foetal complications were assessed. Results Women with T1DM showed lower pregestational BMI (p < 0.001), pregestational weight (p < 0.001), weight at delivery (p < 0.001), ∆_total_insulin requirement (IR) at the first, s…

Adultmedicine.medical_specialtyMultivariate analysisendocrine system diseasesmedicine.medical_treatmentReproductive medicine030209 endocrinology & metabolismAbortionMacrosomialcsh:Gynecology and obstetricsBody Mass IndexFetal Macrosomia03 medical and health sciencesYoung Adult0302 clinical medicinePregnancyRisk FactorsInsulin requirementmedicinePrevalenceHumansInsulinlcsh:RG1-991Retrospective StudiesGlycated HemoglobinPregnancy030219 obstetrics & reproductive medicineObstetricsbusiness.industryInsulinAbortionObstetrics and GynecologyType 2 Diabetes Mellitusnutritional and metabolic diseasesmedicine.diseaseGestational Weight GainAbortion SpontaneousDiabetes Mellitus Type 1Diabetes Mellitus Type 2Large for gestational ageCohortFemalePregnancy Trimestersmedicine.symptomInsulin ResistancebusinessWeight gainResearch Article
researchProduct

Obesity reduces uterine receptivity: clinical experience from 9,587 first cycles of ovum donation with normal weight donors

2013

Objective To analyze the reproductive outcome of recipients of donated ova according to their body mass index (BMI). Design Twelve-year retrospective cohort analysis. Setting Fertility clinics. Patient(s) 9,587 first cycles of ovum donation with ova from normoweight donors. Intervention(s) Recipients divided according to their BMI to analyze IVF laboratory and outcome parameters: lean with BMI 2 (n = 1,458; 15.2%); normoweight with BMI 20–24.9 kg/m 2 (n = 5,706; 59.5%), overweight with BMI 25–29.9 kg/m 2 (n = 1,770; 18.5%), and obese with BMI ≥30 kg/m 2 (n = 653; 6.8%). Main Outcome Measure(s) Implantation, biochemical and clinical pregnancy, miscarriage, and live-birth rates. Result(s) In …

Adultmedicine.medical_specialtyPregnancy RateFertilization in VitroOverweightBody Mass IndexMiscarriagePregnancyRisk FactorsOdds RatioHumansMedicineEmbryo ImplantationObesityTwin PregnancyRetrospective StudiesGynecologyAnalysis of VariancePregnancyChi-Square DistributionOocyte Donationbusiness.industryObstetricsBody WeightUterusnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseaseObesityTissue DonorsAbortion SpontaneousPregnancy rateLogistic ModelsTreatment OutcomeReproductive MedicineSpainPregnancy TwinFemalemedicine.symptomLive birthbusinessInfertility FemaleLive BirthBody mass indexFertility and Sterility
researchProduct